Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Genitourinary × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 34 Other hematologic neoplasm 18 Plasma cell 15 Gynecologic 10 CNS 9 Thoracic 7 Breast 7 Sarcoma 4 Gastrointestinal 4 Myeloid 3 Head & Neck 3 Dermatologic 3 Other solid neoplasm 2 NET 2 Endocrine 2 Genitourinary 1

Conditions

Prostatic Neoplasms 315 Urinary Bladder Neoplasms 97 Carcinoma, Renal Cell 94 Carcinoma, Transitional Cell 50 Neoplasms 47 Breast Neoplasms 44 Kidney Neoplasms 41 Ovarian Neoplasms 39 Colorectal Neoplasms 33 Melanoma 30 Carcinoma, Non-Small-Cell Lung 30 Neoplasm Metastasis 25 Endometrial Neoplasms 25 Lung Neoplasms 24 Non-Muscle Invasive Bladder Neoplasms 22 Pancreatic Neoplasms 20 Uterine Cervical Neoplasms 18 Sarcoma 16 Adenocarcinoma 16 Stomach Neoplasms 15 Esophageal Neoplasms 14 Triple Negative Breast Neoplasms 13 Prostatic Neoplasms, Castration-Resistant 12 Carcinoma, Hepatocellular 12 Squamous Cell Carcinoma of Head and Neck 11 Disease 10 Urethral Neoplasms 9 Head and Neck Neoplasms 9 Clear-cell metastatic renal cell carcinoma 9 Wilms Tumor 8

Interventions

enzalutamide 1 PF06821497 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551324 2026-03-04

MEVPRO-1

Pfizer

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡